RhumbLine Advisers’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $733K | Buy |
83,221
+8,636
| +12% | +$76.1K | ﹤0.01% | 2412 |
|
|
2025
Q1 | $559K | Buy |
74,585
+6,532
| +10% | +$48.9K | ﹤0.01% | 2502 |
|
|
2024
Q4 | $568K | Buy |
68,053
+10,573
| +18% | +$88.2K | ﹤0.01% | 2599 |
|
|
2024
Q3 | $399K | Buy |
57,480
+606
| +1% | +$4.21K | ﹤0.01% | 2863 |
|
|
2024
Q2 | $279K | Buy |
56,874
+8,619
| +18% | +$42.2K | ﹤0.01% | 3042 |
|
|
2024
Q1 | $280K | Buy |
48,255
+1,065
| +2% | +$6.18K | ﹤0.01% | 3019 |
|
|
2023
Q4 | $309K | Buy |
47,190
+1,469
| +3% | +$9.62K | ﹤0.01% | 2950 |
|
|
2023
Q3 | $220K | Buy |
45,721
+2,558
| +6% | +$12.3K | ﹤0.01% | 3110 |
|
|
2023
Q2 | $220K | Buy |
+43,163
| New | +$220K | ﹤0.01% | 3191 |
|
|
2022
Q2 | – | Sell |
-32,381
| Closed | -$163K | – | 3252 |
|
|
2022
Q1 | $163K | Sell |
32,381
-850
| -3% | -$4.28K | ﹤0.01% | 2800 |
|
|
2021
Q4 | $289K | Buy |
33,231
+506
| +2% | +$4.4K | ﹤0.01% | 2718 |
|
|
2021
Q3 | $305K | Buy |
32,725
+893
| +3% | +$8.32K | ﹤0.01% | 2759 |
|
|
2021
Q2 | $408K | Buy |
+31,832
| New | +$408K | ﹤0.01% | 2654 |
|